Extracellular vesicle-delivered siRNA targeting RCN1 suppresses acute myeloid leukemia through TFAM-dependent mtDNA-cGAS-STING signaling
Extracellular Vesicles and Circulating Nucleic Acids · 31.07.2026 · 7 (3) · 1228-48
DOI: 10.20517/evcna.2026.36 ↗Kurz gefasst
Fachartikel in der Zeitschrift Extracellular Vesicles and Circulating Nucleic Acids, online erschienen am 31.07.2026. Verfasst von Huan Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen Bone Marrow Transplantation Public Service Platform, Shenzhen Institute of Hematology, Shenzhen Second People's Hospital, First Affiliated H…. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
Acute myeloid leukemia (AML) remains a highly aggressive hematologic malignancy with limited therapeutic options. This study aimed to elucidate how reticulocalbin-1 (RCN1) regulates mitochondrial DNA (mtDNA)-mediated innate immune signaling in AML and to evaluate the therapeutic potential of extracellular vesicle (EV)-mediated small interfering RNA (siRNA) delivery targeting RCN1.
Methods
Stable RCN1 knockdown was achieved in AML cells using lentiviral delivery of short hairpin RNA. Mitochondrial transcription factor A (TFAM) expression, mtDNA leakage, and activation of the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING)-type I interferon pathway were analyzed by immunoblotting and quantitative polymerase chain reaction. Protein interactions were assessed by co-immunoprecipitation, proximity ligation assay, and immunofluorescence. TFAM rescue experiments were performed to evaluate its contribution to the downstream effects of RCN1 knockdown. For translational evaluation, EVs were isolated and characterized by transmission electron microscopy, nanoparticle tracking analysis, and marker protein detection, followed by loading with siRNA targeting RCN1. Therapeutic efficacy and safety were assessed in an AML xenograft mouse model.
Results
RCN1 knockdown reduced TFAM expression, leading to cytoplasmic mtDNA accumulation and activation of the cGAS-STING-type I interferon signaling pathway. Restoration of TFAM expression attenuated mtDNA leakage and downstream signaling. EV-delivered siRCN1 effectively suppressed tumor growth in vivo without detectable toxicity.
Conclusion
RCN1 silencing destabilizes mtDNA integrity and activates innate immune signaling in AML. EV-based delivery of siRCN1 may represent a promising and potentially safe therapeutic strategy for AML.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Shenzhen Bone Marrow Transplantation Public Service Platform, Shenzhen Institute of Hematology, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen University Health Sciences Ce…
- Institute for Digital Medicine and Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore.
Zitieren
APA
Chen, H., An, N., Yang, L., Lou, J., Pan, Y., Le, M. T. N., Du, X., & Zhang, Q. (2026). Extracellular vesicle-delivered siRNA targeting RCN1 suppresses acute myeloid leukemia through TFAM-dependent mtDNA-cGAS-STING signaling. Extracellular Vesicles and Circulating Nucleic Acids, 7(3), 1228-48. https://doi.org/10.20517/evcna.2026.36
Vancouver
Chen H, An N, Yang L, Lou J, Pan Y, Le MTN, et al. Extracellular vesicle-delivered siRNA targeting RCN1 suppresses acute myeloid leukemia through TFAM-dependent mtDNA-cGAS-STING signaling. Extracellular Vesicles and Circulating Nucleic Acids. 2026;7(3):1228-48. doi:10.20517/evcna.2026.36
BibTeX
@article{Chen2026,
author = {Chen, Huan and An, Na and Yang, Linlin and Lou, Jin and Pan, Yuming and Le, Minh T N and Du, Xin and Zhang, Qiaoxia},
title = {Extracellular vesicle-delivered siRNA targeting RCN1 suppresses acute myeloid leukemia through TFAM-dependent mtDNA-cGAS-STING signaling},
journal = {Extracellular Vesicles and Circulating Nucleic Acids},
year = {2026},
volume = {7},
number = {3},
pages = {1228--48},
doi = {10.20517/evcna.2026.36}
}
EUVIMED